Your browser doesn't support javascript.
loading
Opposite Macrophage Polarization in Different Subsets of Ovarian Cancer: Observation from a Pilot Study.
Vankerckhoven, Ann; Wouters, Roxanne; Mathivet, Thomas; Ceusters, Jolien; Baert, Thaïs; Van Hoylandt, Anaïs; Gerhardt, Holger; Vergote, Ignace; Coosemans, An.
Afiliação
  • Vankerckhoven A; ImmunOvar Research Group, Laboratory of Tumor Immunology and Immunotherapy, Department of Oncology, KU Leuven, 3000 Leuven, Belgium.
  • Wouters R; ImmunOvar Research Group, Laboratory of Tumor Immunology and Immunotherapy, Department of Oncology, KU Leuven, 3000 Leuven, Belgium.
  • Mathivet T; Oncoinvent AS, 0484 Oslo, Norway.
  • Ceusters J; PARCC, HEGP Institute (team 9), INSERM U970, Université Paris Descartes, 75006 Paris, France.
  • Baert T; Vascular Patterning Lab, Center for Cancer Biology, VIB, KU Leuven, 3000 Leuven, Belgium.
  • Van Hoylandt A; ImmunOvar Research Group, Laboratory of Tumor Immunology and Immunotherapy, Department of Oncology, KU Leuven, 3000 Leuven, Belgium.
  • Gerhardt H; ImmunOvar Research Group, Laboratory of Tumor Immunology and Immunotherapy, Department of Oncology, KU Leuven, 3000 Leuven, Belgium.
  • Vergote I; Department of Gynecology and Gynecologic Oncology, Kliniken Essen Mitte (KEM), 45136 Essen, Germany.
  • Coosemans A; ImmunOvar Research Group, Laboratory of Tumor Immunology and Immunotherapy, Department of Oncology, KU Leuven, 3000 Leuven, Belgium.
Cells ; 9(2)2020 01 27.
Article em En | MEDLINE | ID: mdl-32012728
ABSTRACT
The role of the innate immune system in ovarian cancer is gaining importance. The relevance of tumor-associated macrophages (TAM) is insufficiently understood. In this pilot project, comprising the immunofluorescent staining of 30 biopsies taken from 24 patients with ovarian cancer, we evaluated the presence of total TAM (cluster of differentiation (CD) 68 expression), M1 (major histocompatibility complex (MHC) II expression), and M2 (anti-mannose receptor C type 1 (MRC1) expression), and the blood vessel diameter. We observed a high M1/M2 ratio in low-grade ovarian cancer compared to high-grade tumors, more total TAM and M2 in metastatic biopsies, and a further increase in total TAM and M2 at interval debulking, without beneficial effects of bevacizumab. The blood vessel diameter was indicative for M2 tumor infiltration (Spearman correlation coefficient of 0.65). These data mainly reveal an immune beneficial environment in low-grade ovarian cancer in contrast to high-grade serous ovarian cancer, where immune suppression is not altered by neoadjuvant therapy.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Polaridade Celular / Macrófagos Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Polaridade Celular / Macrófagos Idioma: En Ano de publicação: 2020 Tipo de documento: Article